These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 32523332)
1. Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug. Aly UF; Sarhan HA; Ali TFS; Sharkawy HAE Drug Des Devel Ther; 2020; 14():1851-1865. PubMed ID: 32523332 [TBL] [Abstract][Full Text] [Related]
2. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability. Jain S; Reddy VA; Arora S; Patel K Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488 [TBL] [Abstract][Full Text] [Related]
3. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Dudhipala N; Veerabrahma K Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287 [TBL] [Abstract][Full Text] [Related]
4. Solid dispersion systems for enhanced dissolution of poorly water-soluble candesartan cilexetil: In vitro evaluation and simulated pharmacokinetics studies. Ali ISM; Sajad UA; Abdul Rasool BK PLoS One; 2024; 19(6):e0303900. PubMed ID: 38843120 [TBL] [Abstract][Full Text] [Related]
5. Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation. Paudel A; Ameeduzzafar ; Imam SS; Fazil M; Khan S; Hafeez A; Ahmad FJ; Ali A Curr Drug Deliv; 2017; 14(7):1005-1015. PubMed ID: 28034361 [TBL] [Abstract][Full Text] [Related]
6. Preparation, characterization and Amer AM; Allam AN; Abdallah OY Drug Dev Ind Pharm; 2019 Jul; 45(7):1140-1148. PubMed ID: 30912678 [TBL] [Abstract][Full Text] [Related]
7. New supersaturating drug delivery system as strategy to improve apparent solubility of candesartan cilexetil in biorelevant medium. Pinto JMO; Leão AF; Alves GF; Mendes C; França MT; Fernandes D; Stulzer HK Pharm Dev Technol; 2020 Jan; 25(1):89-99. PubMed ID: 31583925 [TBL] [Abstract][Full Text] [Related]
8. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. Zhang Z; Gao F; Bu H; Xiao J; Li Y Nanomedicine; 2012 Jul; 8(5):740-7. PubMed ID: 21930110 [TBL] [Abstract][Full Text] [Related]
9. Enhancement of solubility and permeability of Candesartan cilexetil by using different pharmaceutical interventions. Shaikh SM; Avachat AM Curr Drug Deliv; 2011 Jul; 8(4):346-53. PubMed ID: 21453263 [TBL] [Abstract][Full Text] [Related]
10. Comparative Pharmaceutical Evaluation of Candesartan and Candesartan Cilexetil: Physicochemical Properties, In Vitro Dissolution and Ex Vivo In Vivo Studies. Amer AM; Allam AN; Abdallah OY AAPS PharmSciTech; 2018 Feb; 19(2):661-667. PubMed ID: 28948575 [TBL] [Abstract][Full Text] [Related]
11. A Self-Nanoemulsifying Drug Delivery System for Enhancing the Oral Bioavailability of Candesartan Cilexetil: Ex Vivo and In Vivo Evaluation. AboulFotouh K; Allam AA; El-Badry M; El-Sayed AM J Pharm Sci; 2019 Nov; 108(11):3599-3608. PubMed ID: 31348934 [TBL] [Abstract][Full Text] [Related]
13. DEVELOPMENT OF SOLID LIPID NANOCARRIERS FOR ORAL DELIVERY OF CANDESERTAN CILEXETIL. Ugurlu T; Nalbantoglu A; Sengel-Turk CT Acta Pol Pharm; 2016 Nov; 73(6):1631-1638. PubMed ID: 29634119 [TBL] [Abstract][Full Text] [Related]
14. Candesartan cilexetil loaded nanodelivery systems for improved oral bioavailability. Dudhipala N; Veerabrahma K Ther Deliv; 2017 Feb; 8(2):79-88. PubMed ID: 28088883 [TBL] [Abstract][Full Text] [Related]
15. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles. Nekkanti V; Pillai R; Venkateshwarlu V; Harisudhan T Pharm Dev Technol; 2009; 14(3):290-8. PubMed ID: 19235553 [TBL] [Abstract][Full Text] [Related]
16. Polymorphic and Quantum Chemistry Characterization of Candesartan Cilexetil: Importance for the Correct Drug Classification According to Biopharmaceutics Classification System. de Campos DP; Silva-Barcellos NM; Lima RR; Savedra RML; Siqueira MF; Yoshida MI; da Nova Mussel W; de Souza J AAPS PharmSciTech; 2018 Oct; 19(7):3019-3028. PubMed ID: 30062540 [TBL] [Abstract][Full Text] [Related]
17. Oral bioavailability and intestinal absorption of candesartan cilexetil: role of naringin as P-glycoprotein inhibitor. Gurunath S; Nanjwade BK; Patil PA Drug Dev Ind Pharm; 2015 Jan; 41(1):170-6. PubMed ID: 24168234 [TBL] [Abstract][Full Text] [Related]
18. The effect of PAMAM dendrimer concentration, generation size and surface functional group on the aqueous solubility of candesartan cilexetil. Ertürk AS; Gürbüz MU; Tülü M Pharm Dev Technol; 2017 Feb; 22(1):111-121. PubMed ID: 27484586 [TBL] [Abstract][Full Text] [Related]
19. Three dimensional macroporous hydroxyapatite/chitosan foam-supported polymer micelles for enhanced oral delivery of poorly soluble drugs. Zhang Y; Dong K; Wang F; Wang H; Wang J; Jiang Z; Diao S Colloids Surf B Biointerfaces; 2018 Oct; 170():497-504. PubMed ID: 29960950 [TBL] [Abstract][Full Text] [Related]
20. Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation. Surampalli G; Nanjwade BK; Patil PA; Chilla R Drug Deliv; 2016 Sep; 23(7):2124-2138. PubMed ID: 25080228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]